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AbstrACt
Objective Differences in time intervals to diagnosis 
and treatment between jurisdictions may contribute to 
previously reported differences in stage at diagnosis 
and survival. The International Cancer Benchmarking 
Partnership Module 4 reports the first international 
comparison of routes to diagnosis and time intervals from 
symptom onset until treatment start for patients with lung 
cancer.
Design Newly diagnosed patients with lung cancer, their 
primary care physicians (PCPs) and cancer treatment 
specialists (CTSs) were surveyed in Victoria (Australia), 
Manitoba and Ontario (Canada), Northern Ireland, England, 
Scotland and Wales (UK), Denmark, Norway and Sweden. 
Using Wales as the reference jurisdiction, the 50th, 
75th and 90th percentiles for intervals were compared 
using quantile regression adjusted for age, gender and 
comorbidity.
Participants Consecutive newly diagnosed patients 
with lung cancer, aged ≥40 years, diagnosed between 
October 2012 and March 2015 were identified through 
cancer registries. Of 10 203 eligible symptomatic patients 
contacted, 2631 (27.5%) responded and 2143 (21.0%) 
were included in the analysis. Data were also available 
from 1211 (56.6%) of their PCPs and 643 (37.0%) of their 
CTS.
Primary and secondary outcome measures Interval 
lengths (days; primary), routes to diagnosis and symptoms 
(secondary).
results With the exception of Denmark (−49 days), in 
all other jurisdictions, the median adjusted total interval 
from symptom onset to treatment, for respondents 
diagnosed in 2012–2015, was similar to that of Wales 
(116 days). Denmark had shorter median adjusted primary 
care interval (−11 days) than Wales (20 days); Sweden 
had shorter (−20) and Manitoba longer (+40) median 
adjusted diagnostic intervals compared with Wales (45 
days). Denmark (−13), Manitoba (−11), England (−9) 
and Northern Ireland (−4) had shorter median adjusted 
treatment intervals than Wales (43 days). The differences 
were greater for the 10% of patients who waited the 
longest. Based on overall trends, jurisdictions could be 
grouped into those with trends of reduced, longer and 
similar intervals to Wales. The proportion of patients 
diagnosed following presentation to the PCP ranged from 
35% to 75%.
Conclusion There are differences between jurisdictions 
in interval to treatment, which are magnified in patients 
with lung cancer who wait the longest. The data could help 
jurisdictions develop more focused lung cancer policy and 
strengths and limitations of this study
 ► This is the first study to use standardised survey 
methods and definitions to systematically examine 
key intervals from patients first noticing symptoms 
or bodily changes until the start of treatment for lung 
cancer across multiple jurisdictions.
 ► Recall bias was minimised by the triangulation of 
different data sources and by patients completing 
the questionnaire within a limited time window (me-
dian 5 months) after the cancer diagnosis.
 ► A key limitation, as with all questionnaire- based 
studies, was selection and non- response bias, 
which varied across jurisdictions.
 ► Recruitment of patients up to 9 rather than 6 months 
after diagnosis might have magnified selection bias 
due to high mortality in lung cancer but a sensitivi-
ty analysis suggests that this did not impact on the 
results.
 ► The comparisons for Norway and Victoria are limited 
by small sample size and inclusion of only surgical 
patients, respectively.
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targeted clinical initiatives. Future analysis will explore if these differences 
in intervals impact on stage or survival.
IntrODuCtIOn
Lung cancer is the most common cancer worldwide, 
with nearly 1.83 million cases diagnosed in 2012, and is 
the leading cause of cancer death globally, accounting 
for 19% of cancer deaths.1 Survival is typically low, with 
5- year survival in Europe, North America and Australia 
<20%.2 3 A key factor is diagnosis at advanced stage. 
Reasons for this are multifaceted and include delays due 
to the atypical nature of some presenting symptoms, 
poor sensitivity of chest X- rays and physicians not acting 
quickly enough.4 Within European countries, differences 
of 12 and 5 percentage points in 1- year and 5- year relative 
survival, respectively, have been reported for lung cancers 
diagnosed between 1999 and 2007.5 This and other inter-
national comparisons raises the possibility of additional 
contributory factors such as variations in referral patterns, 
access to diagnostic tests and delays in treatment.6
One way of addressing this is to chart the patient 
journey from ﬁrst noticing symptoms to treatment start. 
Many national studies using different methodologies have 
reported on time intervals to treatment of lung cancer, 
and there are reviews that have looked at international 
time frame comparisons.7–24 However, as far as we are 
aware, there is no study that has undertaken international 
comparisons of timeliness across multiple countries using 
the same methodology.
The International Cancer Benchmarking Partnership 
(ICBP) was established to explore differences in cancer 
outcomes and their causes in countries with comparable 
wealth and universal access to healthcare.25 We report 
results from ICBP Module 4 (ICBP M4) on differences 
in time intervals and routes to diagnosis in symptom-
atic patients with lung cancer from 10 jurisdictions in 
Australia, Canada, Denmark, Norway, Sweden and the 
UK.
MethODs
Methods have been previously detailed.26 In brief, in each 
of the 10 participating jurisdictions (Victoria (Australia), 
Manitoba, Ontario (Canada), Denmark, Norway, Sweden 
Northern Ireland, England, Scotland and Wales), 
consecutive patients aged >40 years, newly diagnosed 
with malignant lung or bronchus cancer (ICD-10 (10th 
revision of the International Statistical Classification of 
Diseases and Related Health Problems): C34.0- C34.9; 
ICD- O-3 behaviour code/3) were identified by the cancer 
registry using validated methods (hospital episode, 
cancer registration and pathology). Exclusion criteria 
included previous lung or synchronous cancers. Patients 
with a previous non- lung primary cancer were eligible. 
Target recruitment was 200 symptomatic patients per 
jurisdiction.
Following a vital status check, cancer registries posted 
the patient questionnaire (online supplementary 
appendix A1) either: (1) to the relevant primary care 
physician (PCP) who then forwarded the preaddressed 
envelope to the patient after confirmation that the 
person was aware of the diagnosis and not deemed too 
sick/anxious to participate in the survey (Wales, England 
and Scotland) or (2) to the patient directly or via the 
research team (remaining seven jurisdictions). In an 
attempt to decrease attrition and recall bias, the protocol 
initially specified that all patient questionnaires should 
be completed within 6 months of diagnosis. As there 
were administrative delays in cancer notification, this was 
extended to 9 months.
On receipt of a completed patient questionnaire, in all 
jurisdictions except Sweden, the relevant PCP and cancer 
treatment specialist (CTS) were sent questionnaires 
(online supplementary appendix A.2 and A.3). Special-
ists provided information on diagnosis and start date of 
treatment. The latter was collected directly from registry 
records in Northern Ireland and clinical databases in 
Denmark. Manitoba did not provide specialist data. Date 
of diagnosis and stage was also collected where possible 
through cancer registries. Information on the types of 
treatment (surgery, chemotherapy, radiotherapy and 
other) were obtained from the patient survey.
Data handling
Data were recoded centrally to ensure that the same 
explicit rules were applied throughout. Patients in whom 
age, date of diagnosis or consent were missing were 
excluded from analyses. Rules were used to combine 
data from the different sources in a standardised way 
that ensured reproducibility and transparency (online 
supplementary appendix B). The rules employed a ‘hier-
archy’ principle in terms of the order in which different 
data sources were used and included imputation rules 
based on the available data. The exact rule was guided 
by the measure in question, for example, patient interval 
was collected primarily from the patient questionnaire 
whereas primary care time- points were collected from 
the PCP questionnaire. We applied rules for outliers and 
implausible measures (eg, negative time intervals were 
recorded to zero- days and intervals longer than a year to 
365 days).
routes to diagnosis and symptoms prompting physician visit
These were derived from patient and PCP responses. 
Symptoms were coded by two PCP authors (DW and PV) 
into ‘lung cancer specific’ or ‘other’ (online supplemen-
tary appendix C1).
time intervals
Time intervals were derived using the checklist for the 
Aarhus Statement.27 The following time- points were used 
to calculate the corresponding time intervals (figure 1):
 ► First noticing symptoms.
 ► First presentation to healthcare
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Figure 1 Time intervals from onset of symptoms to start of treatment based on the Aarhus Statement.
 ► First referral to secondary care.
 ► Diagnosis date.
 ► Start of curative or palliative treatment.
All time- points were validated if there were obvious 
inconsistencies and negative intervals were set to 0 days. 
All intervals were truncated at 365 days. Missing data were 
imputed based on specific rules to ensure that the direc-
tion of a possible misclassification bias was known.
Demographics
Health status was measured using the self- reported 
general health item from Short Form 36 health survey.28 
Comorbidity was defined as one of four patient or 
PCP- reported diseases (heart or lung disease, stroke or 
diabetes) and categorised into: ‘none’, ‘medium’ (one 
or two) or ‘high’ (three or four). Level of educational 
attainment was categorised as ‘low’ (vocational school or 
lower) and ‘high’ (university). Stage data (tumour, node 
and metastasis (TNM) classification) was grouped as I, II, 
III, IV or missing.29
statistical analysis
Patient characteristics across jurisdictions were compared 
using Kruskal- Wallis test for continuous and ordinal data. 
For nominal data, we used Pearson’s χ2 test and Fisher’s 
exact test (if more than 20% of expected cell counts were 
less than five or at least one expected cell count was 0). 
The differences in intervals between the jurisdictions were 
estimated using quantile regression, as this method allows 
for a comparison across the whole distribution of length 
of the interval.30 As we were interested in a measure of 
central tendency of length of the interval and in long and 
very long intervals, the focus of the study was on the 50th 
(median), 75th and 90th interval percentiles. Wales was 
chosen as the reference jurisdiction as it had the lowest 
lung cancer survival in ICBP Module 1 analysis.10 Since 
the length of the interval in days is a continuous measure 
that has been rounded, we applied the quantile regres-
sion analysis on the smoothed quantiles; the method 
based on the smoothed quantiles is recommended for 
analyses of discrete (count) data.31 In STATA, this method 
is implemented in the ‘qcount’ procedure.32 Parameters 
were calculated with 1000 jittered samples. For all interval 
analyses, the differences in intervals were calculated as 
marginal effects after quantile regression by setting the 
continuous covariate (age) to their mean values and the 
categorical covariates (sex and comorbidity) to their 
modes. Significance level was set to <0.05 with 95% CIs 
calculated where appropriate. Statistical analyses were 
carried out using STATA V.14.
sensitivity and validity analyses
All analyses were repeated using only: (1) those who 
fulfilled the 6- month cut- off criteria for interval from 
diagnosis to questionnaire completion and (2) patient 
data. The effect of excluding patients for whom at 
least one interval was missing was investigated. We also 
repeated the analysis after omitting time intervals that 
were negative or over 365 days. Agreement between the 
different data sources (registry, patient, PCP (except in 
Sweden) and CTS (except in Sweden and Manitoba)) was 
measured by Lin’s concordance correlation coefficient 
(CCC).33
Patient involvement
The research questions for this survey drew on an exten-
sive literature relating to diagnosis and treatment delays 
leading to negative patient experiences. While patient 
experience was not a primary outcome measure for this 
study, patients were given the opportunity to comment 
on their experience through questionnaire free- text 
response options (under separate analysis). Patients were 
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involved in the piloting of study instruments to ascertain 
if recruitment and questionnaire content and dissemina-
tion strategies were appropriate, as described elsewhere.26 
Each jurisdiction has committed to communicating the 
findings and local implications of this study to organisa-
tions representing their study participants.
results
Of 14 583 patients with lung cancer, diagnosed between 
October 2012 and March 2015 who were alive when iden-
tified, 70% (10 203/14 583) were contacted (table 1). 
Of 4380 not contacted, 3367 (77%) were from England, 
Wales and Scotland. Major reasons reported by the PCP 
for not forwarding the survey included patients being 
terminally ill, not aware of cancer diagnosis at the time of 
request, having cognitive or visual impairment, language/
communication difficulties, no longer at the address, not 
wishing to take part in research and a small number not 
having the index cancer. In addition, patents identified 
were not contacted in England as the target recruitment 
had been exceeded. For the non- UK jurisdictions, the 
main reasons for not contacting patients were the patient 
having died or no longer at the address.
A total of 2631 (27.5% of contacted, 18% of eligible) 
completed the patient questionnaire at a median of 5 
months (range: 0.1–9) after diagnosis (table 2). The 
response rate of contacted patients varied from 11.1% 
(146/1318) in Norway to 61.8% (333/539) in Denmark. 
Responding patients were more likely to be aged 60–79 
years with less advanced stage (table 1) and alive 1 year 
postdiagnosis (data not shown). Of the 2631 responses, 
2143 (81.5%) were included in the analyses which equates 
to 14.7% (2143/14 583) of eligible patients. The key 
reason respondents were excluded were local oversam-
pling (43.9%; 214/488) for additional analyses (table 1). 
In Victoria, the registry was only able to contact patients 
who had undergone surgery while the sample size in 
Norway was limited (n=88) due to delays in securing 
appropriate approvals.
baseline characteristics
Patient characteristics are detailed in table 2. The cohort 
was predominantly white (95%), median age 70 years 
(IQR 64–75) with 82% reporting ‘low’ levels of education. 
Norway provided stage data classified as local, regional 
and distant, which could not be converted to TNM stage 
data.
Ontario was the only jurisdiction with more female 
(65%) than male respondents. While self- reported health 
differed significantly, with Welsh patients (9%) reporting 
twice as high ‘poor health’ rates than English or Swedish 
(4%) and eightfold that of Manitoba (2%), there was no 
difference in self- reported comorbidity rates. Even after 
the exclusion of Victoria, there was significant variation in 
early stage (I/II) disease, which ranged from 25% (Wales) 
to 59% (Ontario), and surgical resection rates, which 
varied from 27% (Wales) to 58% (Ontario) (table 2).
routes to diagnosis
Results are detailed in table 3. Over half (55%) were diag-
nosed following presentation to the PCP of whom 63% 
(range: 29% Norway–82% Wales; data not shown) were 
urgently referred with a suspicion of cancer based on the 
PCP questionnaire.
symptoms prompting visit to physician
The median number of patient- reported symptoms were 
2 (IQR 1–3). Across jurisdictions, the most common 
patient- reported symptoms were persistent cough (39%), 
breathlessness (37%) and fatigue (27%), although 
there was significant variation in proportion of patients 
presenting with individual symptoms (table 4).
The PCPs reported a median of 1 (IQR 1–2) symptom at 
first presentation, with the most common being persistent 
cough (39%). Across jurisdictions, the reporting of other 
symptoms by the PCP was significantly lower compared 
with patients, especially fatigue (4%) and weight loss 
(8%). When the analysis was restricted to the cohort 
where both patient and PCP had completed the survey, 
this difference persisted. Unlike patients, there was 
minimal variation in PCP reporting of symptoms, with 
significant differences limited to ‘no symptoms’, ‘other 
symptoms not previously listed’ and weight loss. Overall, 
64% of symptoms were labelled as ‘cancer specific’ by the 
study PCPs (table 4).
time intervals
The observed time intervals are shown in online supple-
mentary appendix C2 and are summarised in figure 2. 
Based on overall trends, jurisdictions could be grouped 
into those with reduced, longer and similar intervals to 
Wales (table 5). It was not possible to interpret variations 
observed in Norway (small sample size) and Victoria 
(surgical cohort). In the remaining jurisdictions, there 
was no difference in the median adjusted patient interval 
compared with Wales. Denmark had shorter median 
adjusted primary care interval (−11 days); Sweden had 
shorter (−20) and Manitoba had longer (+40) diagnostic 
intervals compared with Wales. Denmark (−13), Mani-
toba (−11), England (−9) and Northern Ireland (−4) had 
shorter treatment intervals. The median adjusted total 
interval was shorter only in Denmark (table 5, figure 2). 
The differences were greater for the 90th percentile. 
The total interval in patients who waited longest (90th 
percentile) was significantly shorter in two jurisdictions 
(Denmark: −142 days; England: −28 days) compared with 
Wales.
sensitivity and validity analyses
The estimates of routes to diagnosis, time intervals and 
regression analysis trends were not significantly altered by 
changing the cut- off to 6 months or using only patient 
data (results not shown).
Online supplementary appendix C3 details which 
sources were used based on the standardisation rules to 
define dates and also how often a day in the date was 
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imputed. With regards to the dates of first presentation 
to healthcare (CCC=0.91), diagnosis (CCC ≥0.93) and 
treatment (CCC=0.94), there was adequate agreement 
between all data sources where the data on these dates 
was collected. Agreement between patient versus PCP for 
dates of first presentation to healthcare (CCC=0.91) and 
diagnosis (CCC=0.93) was also adequate as was agree-
ment between patient versus CTS for dates of diagnosis 
(CCC=0.94) and treatment (CCC=0.94).
Omitting time intervals that were negative or over 365 
days (online supplementary appendix C4) led to change 
in direction of difference, which was non- significant in 
long intervals (75th or 90th percentile) between Wales 
and jurisdictions in four cases: Norway and Victoria 
(patient interval), Northern Ireland (diagnostic interval) 
and England (total interval). All other results were similar 
to the main results.
DIsCussIOn
Main findings
This is the first international study we are aware of 
comparing lung cancer routes and time intervals. With 
the exception of Denmark, in all other jurisdictions, the 
median total interval from symptom onset to treatment, 
for respondents diagnosed in 2012–2015, was similar to 
that of Wales, which is the reference. However, there were 
jurisdiction specific differences in patient, diagnostic and 
treatment intervals, especially for the 10% of patients 
who waited the longest. Based on overall trends, jurisdic-
tions could be grouped into those with trends of reduced, 
longer and similar intervals to Wales.
Across jurisdictions, all symptoms other than persistent 
cough were less frequently reported by the PCP when 
compared with patients. This was especially true for 
fatigue and weight loss. One in four patients reported inci-
dental diagnosis and 1 in 10 were diagnosed following a 
visit to the emergency (Accident and Emergency (A&E)) 
department.
strengths and weaknesses
Our study helps address the shortcomings of current 
international comparisons across multiple national 
studies with significant variation in methodology 
including differences in definition of intervals. 
Strengths of our study include: (1) use of the same 
methodology across countries; (2) use of cancer regis-
tries to identify consecutive newly diagnosed patients; 
(3) use of standardised questionnaires; (4) inclusion of 
PCP and CTS questionnaires enriched by registry data; 
(5) minimal data interpretation by the local teams with 
all data cleaning performed in a standardised manner 
centrally; and (6) triangulation with comprehensive 
data rules to ensure validity, consistency and preserve 
statistical precision.21 Recall bias was minimised by the 
triangulation of different data sources and by patients 
completing the questionnaire within a limited time 
window (median 5 months) after the cancer diagnosis.
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A key limitation, as with all questionnaire- based 
studies, was both selection and non- response bias 
that varied across jurisdictions and has implications 
for interpretation and generalisation of findings.34 
In comparing intervals, we adjusted for age, sex and 
comorbidity but were unable to adjust for ethnicity and 
education due to different classification systems. Recall 
bias was minimised by the triangulation of different 
data sources and by patients completing the question-
naire within a limited time window (median 5 months) 
after the cancer diagnosis. Recruitment of patients up 
to 9 rather than 6 months after diagnosis might have 
magnified the selection bias due to high mortality.35 
However, sensitivity analysis suggests that this did not 
impact on the results. Categorising presenting symp-
toms into indicative or not was done pragmatically as 
existing guidelines for lung cancer investigation vary 
across ICBP jurisdictions.36 In Norway and Victoria, a 
small sample size and restriction of eligibility to only 
surgical patients, respectively, made comparison diffi-
cult. Nonetheless, significant differences in these two 
jurisdictions compared with Wales were largely limited 
to the treatment interval alone.
There was variation in stage distribution across juris-
dictions. While this may be partly related to the varying 
response rate, true differences in lung cancer stage have 
been noted on analysis of registry data of patients diag-
nosed between 2004 and 2007.6 The high lung cancer 
mortality and self- selection are likely to have contrib-
uted to an over- representation of early stage disease and 
tumours treated with surgical resection. This suggests 
that true variation may well be higher than that reported 
in this cohort of ‘healthier early stage’ patients.
Comparison with other studies
The most common patient- reported symptoms, in keeping 
with the literature, were persistent cough, breathless-
ness, fatigue and weight loss, with one in five reporting 
‘no symptoms’.18 Only a minority (11%) of our respon-
dents reported coughing blood or bloody sputum/spit, 
which is the only consistent predictor of lung cancer.37 
While haemoptysis was reported in a prospective survey 
(England 2011–2012) by 22% of patients with lung cancer 
identified through respiratory clinics, it was a presenting 
symptom in only 5% of cases.11
The median number of symptoms reported by 
patients was more than that reported by the PCP in 
all jurisdictions. This was especially so for fatigue and 
weight loss. A number of factors could have contributed 
to this: patients not listing all symptoms at presentation, 
patients having a different understanding/recall of 
their symptoms post diagnosis and PCPs only recording 
key symptoms such as cough. Further research on 
under- reporting of systemic symptoms such as fatigue 
and weight loss is warranted.
As lung cancer mortality is higher in patients attending 
emergency (A&E) departments, the rates are often 
compared in an attempt to understand international 
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Figure 2 Differences in 50th, 75th and 90th centiles of the intervals (days) between Wales as the reference and the other 
nine jurisdictions. The data are adjusted for differences in age, gender and comorbidity. The bars in black show significant 
differences in intervals.
survival differences.38 The rate of respondents who 
attended A&E varied twofold across jurisdictions from 
9%–10% in England, Scotland and Denmark to 18%–20% 
in Northern Ireland, Ontario and Manitoba. While rates 
for Scotland (10%) were similar to that reported in a 
prospective Scottish audit (11.5%), as were rates for 
Denmark (7% vs 6.3% when PCP not involved), rates 
for England (9%) were lower than those reported in 
population based audits (25%) reflecting non- response 
bias.14 15 In Victoria (4%), restriction of the cohort to 
surgical patients is likely to have accounted for the very 
low rates.
Our reported median patient, primary care and diag-
nostic intervals are in keeping with those previously 
reported from the participating jurisdictions (table 6). 
Minor variations in interval estimates are likely due to 
differences in data source, sample size and cohort char-
acteristics.39 Longer intervals were reported from earlier 
cancer cohorts: median primary care interval for England 
of 52 days in 1998–2000 (our median 11),13 median total 
interval for Denmark of 108 days in 2004–2005 (our 
median 67) and Norway of 118 in 2002–5 (our median 
79).17–19 24
Across all jurisdictions, there was no significant differ-
ence in primary care intervals for the 10% of patients 
with longest interval. It is likely that these patients had 
vague or non- specific symptoms and signs. Referral 
guidelines for suspected lung cancer do not always 
favour patients with early symptoms and often prior-
itise those with more advanced disease.40 Access to 
better diagnostic tools such as low- dose CT chest in the 
primary care setting may favour this group of patients.41 
It would be useful in future projects to explore whether 
such access may have contributed to the improved 
1- year lung cancer survival reported from Australia and 
Canada.6
Diagnostic intervals were significantly longer for Mani-
toba compared with other jurisdictions and twice that 
reported in an ongoing local PCP audit (personal commu-
nication). While one might suspect overestimation due 
to differences in the source of date of first presentation, 
between our study (in almost half, it was derived from 
patients) and local audit, this is less likely as the concor-
dance coefficient between PCP and patient derived data 
at Manitoba was 0.94.
Observed median treatment intervals were below 
6 weeks for nearly all jurisdictions. This was the only 
interval where there were significant differences 
between jurisdictions with Denmark, England, Norway 
and Northern Ireland all having shorter adjusted 
treatment intervals across all percentiles, with larger 
differences for the 75th and 90th percentile. These 
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improvements may reflect implementation of waiting 
time targets in Denmark (35–38 days from first consulta-
tion depending on treatment modality) and the UK (31 
days from decision to treat).42 43 The shorter treatment 
intervals in Norway are in keeping with long- standing 
provision of standardised cancer care pathways and 
effective coordination between primary care and treat-
ment centres. While a systematic review did not find 
evidence to support an association between intervals 
and lung cancer outcomes, increasing mortality with 
longer diagnostic intervals was noted in a more recent, 
high- quality study.16 In 2000, O’Rourke and Edwards 
reported median intervals of 94 days (35–187) between 
the first hospital visit and starting treatment resulting 
in 21% of potentially curable patients becoming incur-
able.44 Others have found metabolic evidence on PET/
CT of pretreatment disease progression in 21% and 
TNM upstaging in 18% of small- cell lung cancer patients 
after a relatively short median interscan interval of 43 
days.45 Long intervals can also result in deterioration in 
performance status. More recently, there is concern that 
the need for genotyping may result in further increase 
in time to treatment.
The shorter total interval in Denmark likely reflects 
the significant reductions in cancer waiting times 
following a collaborative effort to set- up and implement 
a national centralised quality management system, the 
Danish Cancer Patient Pathways (CPPs). The latter 
includes PCP access to fast- track diagnostic work- up.46 
The findings are in keeping with higher relative survival 
and lower mortality in Denmark among symptomatic 
cancer patients diagnosed through primary care after 
the implementation of CPPs and with the accelerated 
increase in 5- year survival among Danish patients with 
lung cancer diagnosed in 2010–2014 when compared 
with patients from earlier time periods.47 48 While there 
is some inherent lead- time bias, the findings highlight 
the importance and feasibility of a timely diagnosis of 
lung cancer.
COnClusIOns
The study provides for the first time, comparable data, 
collected through consistent methods in all jurisdic-
tions, allowing for detailed comparisons of key diag-
nostic intervals in lung cancer and routes to diagnosis. 
While all jurisdictions except Denmark had similar 
median adjusted total intervals, there were jurisdiction- 
specific significant differences in patient, diagnostic and 
treatment intervals, especially for the 10% of patients 
who waited the longest. The proportion of patients 
diagnosed following presentation to the PCP ranged 
from 35% to 75%. These data could help individual 
jurisdictions to better target their efforts to reduce time 
to treatment and ultimately improve patient experience 
and outcomes in lung cancer.
Intervals and pathways are ultimately of interest as 
they relate to prognosis. A further analysis that includes 
all four cancers (lung, ovary, colon and breast) surveyed 
in ICBP4 module and explores the impact of these 
intervals on stage and 1- year survival is underway.
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